Ozempic is changing the brain in ways that surprise scientists

illuminem summarises for you the essential news of the day, reviewed by our editorial team. Read the full piece on The Washington Post or enjoy below:

🗞️ Driving the news: GLP-1 drugs like Ozempic and Mounjaro, originally developed for obesity and diabetes, are showing unexpected neurological effects
• Brain scans from a study at the University of Colorado Anschutz suggest these medications may rewire circuits involved in attention, reward, motivation, and emotion
• Millions of users worldwide are now part of a de facto large-scale neuroscience experiment

🔭 The context: GLP-1 hormones, targeted by these drugs, naturally regulate appetite and digestion but they have receptors in multiple brain regions
• Research indicates they may influence dopamine-driven reward pathways, stress, and cognitive function
• Clinical trials are exploring their potential in addiction, psychiatric conditions, and neurodegenerative disease, though results remain preliminary
• Side effects reported include brain fog, emotional flattening, and reduced motivation

🌍 Why it matters for the planet: Widespread neurological use of GLP-1 drugs has systemic implications for public health
• Behavioral shifts, such as reduced caloric intake or altered activity patterns, may indirectly affect energy consumption, food production, and healthcare resource allocation, linking individual metabolic interventions to broader societal impacts

⏭️ What’s next: Researchers are expanding studies to adolescents and exploring long-term cognitive effects, with particular attention to whether neural changes persist after discontinuation
• Further trials on addiction, schizophrenia, and Alzheimer’s prevention are underway

💬 One quote: “We didn’t expect to see this effect, and we really don’t know what it means.” — Allison Shapiro, University of Colorado Anschutz

📈 One stat: Tens of millions of people worldwide are now taking GLP-1 drugs, creating one of the largest unplanned neuroscience cohorts in modern medicine

Track the real‑world impact behind the sustainability headlines. Illuminem’s Data Hub™ offers transparent performance data and climate targets of companies driving the transition.

Click for more news covering the latest on wellbeing